Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Neoadjuvant GEMABR for Borderline Resectable Pancreatic Cancer
NCT02506803Phase 1Unknown
- Sponsor
- Wakayama Medical University
- Start
- Jul 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic cancer (PC), sponsored by Wakayama Medical University. Primary endpoint: Number of participants with toxicity up to 30 weeks. Status: unknown.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02506803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506803.